Key takeaways
- Signal-based GTM adds a live layer on top of the usual firmographic fit gate: it watches for events like funding, hiring, trial milestones, and regulatory designations to decide when to reach out.
- Unlike general B2B intent data, life science buying signals (a phase transition, an IND filing, a funding close) are directly observable in public sources rather than inferred from anonymized behavior.
- It replaces a fixed prospecting cadence with signal-driven timing, so an account with a fresh, strong signal moves ahead of one just sitting on a monitored list.
- Life science budgets tend to arrive in discrete, publicly documented bursts, which is part of why a signal-based approach works especially well in this industry.
Signal-based GTM for life science is a go-to-market approach that targets and times outreach using public, industry-specific buying signals such as funding, hiring, clinical trial milestones, regulatory events, and publications, rather than relying only on static firmographic fit or generic B2B intent data. It is Arcova's framing for a go-to-market model built around observable events instead of a fixed target list.
What signal-based GTM means in practice
A signal-based approach still starts with a firmographic fit gate, same as any other GTM model: therapeutic area, modality, development stage, company size, buyer function. What changes is what happens after that gate. Instead of working the fit-qualified list on a fixed calendar, a signal-based approach watches for specific, dated events at those accounts, a funding close, a hire, a trial phase transition, a regulatory designation, a conference confirmation, and lets that activity determine which accounts move to active outreach, and when.
The result is a working list that is constantly re-ranked by what has actually changed recently, rather than a static list that gets worked top to bottom regardless of timing. See readiness scoring for how that ranking is typically structured into a comparable score per account.
Signal-based GTM vs. intent-based GTM
Intent-based GTM, as the term is generally used in B2B software sales, infers buyer interest from content consumption and search behavior: which topics a company's employees are researching, which pages they are visiting, which third-party research they are engaging with. That data is genuinely useful in categories where the buying process is largely a private research exercise.
Life science buying triggers are different in kind. A CRO or CDMO evaluation rarely starts because someone read an article; it starts because a trial hit a phase transition, an IND was filed, or a funding round closed and now needs to be deployed. Those events are directly observable in public sources rather than inferred from anonymized behavioral data, which is what makes a signal-based approach both more precise and more explainable than generic intent data in this industry.
Signal-based GTM vs. list-based prospecting
Traditional list-based prospecting builds a static account list from firmographic filters and works it on a fixed cadence, a set number of touches per account per month, regardless of what is happening at any given account this week. It treats every fit-qualified account as equally timely, which is rarely true.
Signal-based GTM keeps the firmographic filter as the starting gate but replaces the fixed cadence with signal-driven timing: an account with no recent activity stays on a monitoring cadence, while an account with a fresh, strong signal moves to active outreach immediately. This tends to produce both higher response rates, because outreach lands closer to an actual moment of need, and less wasted effort on accounts that are technically in-market but have no current reason to engage.
Why timing carries this much weight in life science
Budget and mandate in life science tend to arrive in discrete bursts tied to funding events, trial milestones, and regulatory gates, rather than building up gradually through a slow internal evaluation process. Those events are also unusually well documented publicly compared with many other B2B categories, clinical trial registries, FDA databases, funding announcements, which is part of why a signal-based approach is practical to run at scale in life science specifically. See the life science GTM glossary for the broader vocabulary this approach draws on.